NEW YORK (GenomeWeb News) - Dutch diagnostics maker Agendia said today it has joined the Personalized Medicine Coalition, a consortium focused on public policy and regulatory issues related to the adoption of personalized medicine.
Agendia makes MammaPrint, an in vitro diagnostic multivariate index assay for breast cancer recurrence that was the first such test to be cleared by the US Food and Drug Administration.
Now that the Amsterdam-based firm is marketing the test in the US, "we believe it is now time to actively participate in the discussion about the implementation of personalized medicine in the US," company CEO Bernhard Sixt said in a statement.